Scilex Holding Company's ability to collect accounts receivable sequentially worsen to 1.93, pointing to a challenging and on top of that deteriorating business climate for the Biotechnology & Pharmaceuticals industry. Scilex Holding's Accounts Receivable average collection period in the Jun 30 2026 quarter, has increased to 189 days, from 171 days, in the Mar 31 2026 quarter.

If we take a look into Healthcare sector 500 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Jun 30 2026 from 2806 to 3219.

What is Receivable Turnover Ratio?
What is Scilex Holding Company Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

SCLX Receivables Turnover Ratio	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Receivable Change	14.51 %	80.81 %	-42.35 %	-62.19 %	-55.88 %
Y / Y Revenue Change	-22.78 %	72.12 %	-67.83 %	-26.85 %	-39.55 %
Receivable Turnover Ratio (TTM)	1.93	2.14	2.22	2.45	2.07
SCLX's Total Ranking	# 3219	# 2806	# 2925	# 2779	# 1600
Accounts Receivable average collection period days	189	170	165	149	176
Seq. Receivable Change	0 %	25.95 %	27.66 %	-28.78 %	57.9 %
Seq. Revenue Change	-11.27 %	79.7 %	-54.61 %	6.71 %	97.76 %

Receivable Turnover Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 59
Healthcare Sector	# 501
Overall Market	# 3219

Receivable Turnover Ratio Statistics
High	Average	Low
3.38	2.08	1.65
(Sep 30 2023)		(Sep 30 2024)

News about Scilex Holding Company Receivables Turnover Ratios

Scilex Bio and NeuroBiogen Forge Strategic Alliance for Global Development and Commercialization of KDS2010 in Cardio...

: In a groundbreaking development within the global pharmaceutical landscape, Scilex Bio, a significant part of the Scilex Holding Company, has entered into a binding agreement with NeuroBiogen for a global license of the KDS2010 drug candidate. This agreement marks a significant step toward the commercialization and extensive research into a novel oral tablet aimed at a wide array of cardio-metabolic and neurodegenerative diseases, including obesity, type 2 diabetes, Alzheimer s, Parkinson s, and other CNS diseases. This article delves into the strategic partnership, the scientific promise of KDS2010, and the potential impacts on current and future therapeutic landscapes.The realm of drug development for cardio-metabolic and neurodegenerative diseases is on the cusp of a major breakthrough with the recent collaboration between Scilex Bio and NeuroBiogen. The binding term sheet signed between these two prominent entities represents a significant advancement in global pharmaceutical ventures, holding promise for comprehensive solutions targeting various disease indications.

SCLX Company Profile • Back to SCLX Efficiency Comparisons • Compare SCLX Receivables Turnover Ratio to its Competitors

Financial Statements
Scilex Holding's Accounts Receivable	$ 19 Millions	Visit SCLX's Balance sheet
Scilex Holding's Sales TTM	$ 32 Millions	Visit SCLX's Income Statement
Sources of SCLX's Revenues		Visit SCLX's Sales by Geography

Other Accounts Receivable Turnover Ratios
Biotechnology & Pharmaceuticals Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
SCLX's Receivable Turnover Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
SCLX's Growth Rates	SCLX's Roa	SCLX's Inventory Turnover Ratio	SCLX's Dividend Comparisons
SCLX's Profitability Ratios	SCLX's Roi	SCLX's Asset Turnover Ratio	SCLX's Dividend Growth
SCLX's Valuation Ratios	SCLX's Roe	SCLX's Financial Strength Ratios	SCLX's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Jun 30 2026	Receivable at quarter ending Jun 30 2026
Bioventus Inc	4.49	$ 581.106 Millions	$ 129.410 Millions
Bionexus Gene Lab Corp	4.48	$ 3.127 Millions	$ 0.697 Millions
Omniab Inc	4.48	$ 38.457 Millions	$ 8.588 Millions
Bellevue Life Sciences Acquisition Corp	4.47	$ 1.809 Millions	$ 0.404 Millions
Vaso Corporation	4.44	$ 80.220 Millions	$ 18.048 Millions
Qt Imaging Holdings Inc exact Name Of Registrant As Specified In Its Charter _______________________	4.40	$ 25.185 Millions	$ 5.729 Millions
Neurocrine Biosciences Inc	4.40	$ 3,373.900 Millions	$ 767.475 Millions
Globus Medical Inc	4.33	$ 3,144.934 Millions	$ 726.626 Millions
Organon and Co	4.31	$ 6,139.000 Millions	$ 1,422.750 Millions
Alkermes Plc	4.30	$ 1,667.652 Millions	$ 388.132 Millions
Glaukos Corp	4.29	$ 500.031 Millions	$ 116.471 Millions
Lantheus Holdings Inc	4.24	$ 1,555.343 Millions	$ 367.122 Millions
Apyx Medical Corp	4.14	$ 58.105 Millions	$ 14.035 Millions
Regenxbio Inc	4.13	$ 174.482 Millions	$ 42.238 Millions
Inspiremd Inc	4.12	$ 10.502 Millions	$ 2.550 Millions
Nexalin Technology Inc	4.07	$ 0.217 Millions	$ 0.053 Millions
Medinotec Inc	4.07	$ 10.247 Millions	$ 2.519 Millions
Outset Medical Inc	4.06	$ 117.551 Millions	$ 28.959 Millions
Ironwood Pharmaceuticals inc	4.04	$ 389.316 Millions	$ 96.422 Millions
Pelthos Therapeutics Inc	4.03	$ 43.304 Millions	$ 10.757 Millions
Revvity Inc	4.03	$ 2,911.811 Millions	$ 723.421 Millions
Gyre Therapeutics Inc	4.02	$ 119.383 Millions	$ 29.697 Millions
Vaxart Inc	4.02	$ 243.064 Millions	$ 60.514 Millions
Pro dex Inc	4.01	$ 77.548 Millions	$ 19.357 Millions
Xencor Inc	3.99	$ 104.973 Millions	$ 26.335 Millions
Bridgebio Pharma Inc	3.99	$ 713.069 Millions	$ 178.918 Millions
Biomerica Inc	3.97	$ 4.453 Millions	$ 1.121 Millions
Retractable Technologies Inc	3.95	$ 33.488 Millions	$ 8.484 Millions
Teva Pharmaceutical Industries Limited	3.92	$ 14,105.000 Millions	$ 3,601.250 Millions
Teleflex Incorporated	3.90	$ 1,628.534 Millions	$ 417.093 Millions

Date modified: 2026-08-17T17:20:43+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.